Compare XPRO & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XPRO | STOK |
|---|---|---|
| Founded | 1938 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2013 | 2019 |
| Metric | XPRO | STOK |
|---|---|---|
| Price | $16.42 | $33.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $15.25 | ★ $36.10 |
| AVG Volume (30 Days) | ★ 1.2M | 702.1K |
| Earning Date | 05-19-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | 0.45 | ★ 0.85 |
| Revenue | ★ $522,493,000.00 | $36,555,000.00 |
| Revenue This Year | $6.71 | $428.68 |
| Revenue Next Year | $2.10 | N/A |
| P/E Ratio | ★ $35.89 | $39.05 |
| Revenue Growth | 14.89 | ★ 316.34 |
| 52 Week Low | $6.70 | $5.35 |
| 52 Week High | $18.73 | $40.22 |
| Indicator | XPRO | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 47.93 |
| Support Level | $15.23 | $31.60 |
| Resistance Level | $16.95 | $35.75 |
| Average True Range (ATR) | 0.78 | 2.31 |
| MACD | -0.18 | -0.29 |
| Stochastic Oscillator | 26.61 | 16.80 |
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA); and Asia-Pacific (APAC). The majority of its revenue is derived from the North and Latin America (NLA) segment.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.